Sachin Wani
Concepts (623)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 107 | 2025 | 158 | 32.840 |
Why?
| | Esophageal Neoplasms | 81 | 2025 | 333 | 22.210 |
Why?
| | Adenocarcinoma | 65 | 2025 | 892 | 11.570 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 44 | 2025 | 212 | 10.340 |
Why?
| | Esophagoscopy | 55 | 2025 | 213 | 10.160 |
Why?
| | Endosonography | 38 | 2024 | 153 | 9.210 |
Why?
| | Gastroenterology | 29 | 2025 | 182 | 8.470 |
Why?
| | Endoscopy, Gastrointestinal | 42 | 2024 | 232 | 7.870 |
Why?
| | Precancerous Conditions | 29 | 2025 | 166 | 7.630 |
Why?
| | Endoscopy, Digestive System | 24 | 2023 | 135 | 6.830 |
Why?
| | Quality Indicators, Health Care | 19 | 2024 | 308 | 6.280 |
Why?
| | Colonoscopy | 33 | 2025 | 250 | 6.250 |
Why?
| | Colonic Polyps | 22 | 2025 | 82 | 5.770 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 19 | 2024 | 56 | 5.080 |
Why?
| | Gastroesophageal Reflux | 19 | 2023 | 242 | 4.470 |
Why?
| | Clinical Competence | 28 | 2025 | 1202 | 4.350 |
Why?
| | Esophagus | 21 | 2021 | 257 | 3.920 |
Why?
| | Pancreatic Neoplasms | 23 | 2024 | 882 | 3.260 |
Why?
| | Learning Curve | 13 | 2024 | 70 | 3.180 |
Why?
| | Endoscopic Mucosal Resection | 11 | 2024 | 27 | 2.920 |
Why?
| | Pancreatitis | 16 | 2025 | 136 | 2.800 |
Why?
| | Adenoma | 17 | 2023 | 220 | 2.770 |
Why?
| | Population Surveillance | 12 | 2024 | 481 | 2.750 |
Why?
| | Gastrointestinal Diseases | 9 | 2022 | 207 | 2.690 |
Why?
| | Humans | 299 | 2026 | 141187 | 2.490 |
Why?
| | Endoscopy | 15 | 2021 | 322 | 2.400 |
Why?
| | Biopsy | 23 | 2023 | 1081 | 2.100 |
Why?
| | Cholangitis | 6 | 2024 | 19 | 1.950 |
Why?
| | Stents | 17 | 2025 | 529 | 1.880 |
Why?
| | Colorectal Neoplasms | 14 | 2023 | 802 | 1.870 |
Why?
| | Pancreatic Cyst | 4 | 2020 | 48 | 1.840 |
Why?
| | Watchful Waiting | 8 | 2021 | 84 | 1.650 |
Why?
| | Catheter Ablation | 8 | 2022 | 313 | 1.650 |
Why?
| | Guideline Adherence | 5 | 2021 | 565 | 1.640 |
Why?
| | Narrow Band Imaging | 8 | 2022 | 14 | 1.600 |
Why?
| | Prospective Studies | 46 | 2024 | 7739 | 1.580 |
Why?
| | Societies, Medical | 9 | 2024 | 855 | 1.550 |
Why?
| | Fellowships and Scholarships | 5 | 2024 | 319 | 1.540 |
Why?
| | Sphincterotomy, Endoscopic | 10 | 2024 | 29 | 1.480 |
Why?
| | Disease Progression | 21 | 2025 | 2793 | 1.440 |
Why?
| | Bile Duct Neoplasms | 4 | 2021 | 114 | 1.430 |
Why?
| | Pancreatic Diseases | 10 | 2020 | 67 | 1.390 |
Why?
| | Education, Medical, Graduate | 8 | 2024 | 522 | 1.350 |
Why?
| | Hyperplasia | 8 | 2024 | 176 | 1.350 |
Why?
| | Middle Aged | 97 | 2026 | 34434 | 1.240 |
Why?
| | Fiducial Markers | 2 | 2019 | 9 | 1.230 |
Why?
| | Aged | 78 | 2025 | 24574 | 1.210 |
Why?
| | Pancreas | 10 | 2024 | 326 | 1.190 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2024 | 76 | 1.160 |
Why?
| | United States | 40 | 2025 | 15220 | 1.100 |
Why?
| | Male | 112 | 2026 | 69783 | 1.090 |
Why?
| | Needles | 5 | 2024 | 63 | 1.040 |
Why?
| | Ampulla of Vater | 4 | 2023 | 34 | 1.040 |
Why?
| | Registries | 8 | 2022 | 2135 | 1.020 |
Why?
| | Female | 109 | 2026 | 75515 | 1.010 |
Why?
| | Choledocholithiasis | 3 | 2023 | 19 | 1.010 |
Why?
| | Ablation Techniques | 4 | 2024 | 34 | 1.010 |
Why?
| | Benchmarking | 4 | 2022 | 188 | 1.000 |
Why?
| | Esophagitis, Peptic | 3 | 2023 | 17 | 0.980 |
Why?
| | Esophagectomy | 7 | 2023 | 137 | 0.980 |
Why?
| | Catheterization | 9 | 2024 | 182 | 0.970 |
Why?
| | Biopsy, Fine-Needle | 4 | 2017 | 70 | 0.970 |
Why?
| | Esophageal Achalasia | 3 | 2021 | 28 | 0.960 |
Why?
| | Rectum | 2 | 2019 | 191 | 0.950 |
Why?
| | Intestinal Polyps | 2 | 2016 | 15 | 0.950 |
Why?
| | Practice Guidelines as Topic | 12 | 2025 | 1597 | 0.920 |
Why?
| | Digestive System Diseases | 3 | 2015 | 26 | 0.920 |
Why?
| | Gastrointestinal Hemorrhage | 5 | 2024 | 134 | 0.900 |
Why?
| | Aptitude | 2 | 2015 | 37 | 0.890 |
Why?
| | Biliary Tract Diseases | 5 | 2020 | 33 | 0.890 |
Why?
| | Laryngopharyngeal Reflux | 2 | 2021 | 15 | 0.890 |
Why?
| | Pepsin A | 2 | 2021 | 19 | 0.880 |
Why?
| | Self-Assessment | 1 | 2025 | 76 | 0.870 |
Why?
| | Observer Variation | 13 | 2017 | 355 | 0.870 |
Why?
| | Practice Patterns, Physicians' | 6 | 2021 | 1336 | 0.860 |
Why?
| | Self Expandable Metallic Stents | 2 | 2021 | 16 | 0.860 |
Why?
| | Pancreatic Ducts | 7 | 2024 | 79 | 0.860 |
Why?
| | Margins of Excision | 1 | 2024 | 48 | 0.850 |
Why?
| | Lymph Nodes | 4 | 2015 | 502 | 0.830 |
Why?
| | Taurine | 1 | 2023 | 40 | 0.820 |
Why?
| | Colonic Pseudo-Obstruction | 2 | 2020 | 4 | 0.810 |
Why?
| | Neoplasm Staging | 8 | 2024 | 1398 | 0.800 |
Why?
| | Intestinal Volvulus | 2 | 2020 | 23 | 0.780 |
Why?
| | Time-to-Treatment | 1 | 2024 | 217 | 0.780 |
Why?
| | Drainage | 8 | 2024 | 174 | 0.760 |
Why?
| | Early Detection of Cancer | 13 | 2024 | 441 | 0.760 |
Why?
| | Incidence | 19 | 2025 | 2794 | 0.760 |
Why?
| | Disease Management | 3 | 2021 | 633 | 0.750 |
Why?
| | Stomach Diseases | 2 | 2014 | 19 | 0.740 |
Why?
| | Treatment Outcome | 29 | 2025 | 11120 | 0.740 |
Why?
| | Cholestasis | 3 | 2021 | 207 | 0.730 |
Why?
| | Postoperative Complications | 6 | 2025 | 2797 | 0.730 |
Why?
| | Rectal Diseases | 2 | 2019 | 24 | 0.730 |
Why?
| | Endoscopes | 2 | 2021 | 17 | 0.710 |
Why?
| | Teaching Rounds | 1 | 2022 | 72 | 0.700 |
Why?
| | Deglutition Disorders | 2 | 2021 | 148 | 0.700 |
Why?
| | Equipment Reuse | 1 | 2021 | 16 | 0.680 |
Why?
| | Esophageal Sphincter, Lower | 2 | 2021 | 14 | 0.680 |
Why?
| | Esophageal Diseases | 2 | 2014 | 28 | 0.680 |
Why?
| | Referral and Consultation | 4 | 2024 | 798 | 0.680 |
Why?
| | Dilatation | 3 | 2019 | 69 | 0.670 |
Why?
| | Argon Plasma Coagulation | 1 | 2020 | 6 | 0.670 |
Why?
| | Retrospective Studies | 37 | 2026 | 16273 | 0.670 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2023 | 1073 | 0.670 |
Why?
| | Hemostasis, Endoscopic | 1 | 2020 | 1 | 0.670 |
Why?
| | Pancreatectomy | 3 | 2021 | 262 | 0.660 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1251 | 0.660 |
Why?
| | Sensitivity and Specificity | 19 | 2023 | 1973 | 0.660 |
Why?
| | Competency-Based Education | 2 | 2024 | 75 | 0.650 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2017 | 38 | 0.650 |
Why?
| | Delphi Technique | 6 | 2024 | 308 | 0.650 |
Why?
| | Heller Myotomy | 1 | 2019 | 2 | 0.640 |
Why?
| | Acetylcholine Release Inhibitors | 1 | 2019 | 4 | 0.640 |
Why?
| | Sigmoid Diseases | 1 | 2019 | 14 | 0.630 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 28 | 0.630 |
Why?
| | Cholinesterase Inhibitors | 1 | 2019 | 38 | 0.630 |
Why?
| | Bile Ducts | 3 | 2014 | 66 | 0.630 |
Why?
| | SEER Program | 4 | 2020 | 220 | 0.630 |
Why?
| | Proctoscopy | 1 | 2019 | 6 | 0.620 |
Why?
| | Carcinoma | 3 | 2021 | 230 | 0.610 |
Why?
| | Risk Factors | 23 | 2025 | 10438 | 0.610 |
Why?
| | Conservative Treatment | 1 | 2019 | 35 | 0.610 |
Why?
| | Botulinum Toxins | 1 | 2019 | 45 | 0.610 |
Why?
| | Medical Overuse | 1 | 2019 | 33 | 0.610 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 37 | 0.600 |
Why?
| | Decompression, Surgical | 1 | 2019 | 113 | 0.600 |
Why?
| | Quality of Health Care | 2 | 2021 | 658 | 0.600 |
Why?
| | Racism | 1 | 2021 | 139 | 0.590 |
Why?
| | Colonic Neoplasms | 7 | 2022 | 246 | 0.580 |
Why?
| | Acute Disease | 8 | 2024 | 1008 | 0.580 |
Why?
| | Family Health | 1 | 2019 | 194 | 0.560 |
Why?
| | Stomach Neoplasms | 4 | 2024 | 118 | 0.560 |
Why?
| | Conflict of Interest | 1 | 2020 | 130 | 0.560 |
Why?
| | Intestinal Perforation | 2 | 2016 | 45 | 0.560 |
Why?
| | Radiation Injuries | 1 | 2019 | 149 | 0.550 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 178 | 0.550 |
Why?
| | Adult | 48 | 2026 | 39177 | 0.540 |
Why?
| | Prosthesis Implantation | 1 | 2019 | 157 | 0.540 |
Why?
| | Cytological Techniques | 1 | 2017 | 28 | 0.540 |
Why?
| | Time Factors | 14 | 2025 | 6956 | 0.540 |
Why?
| | Cathartics | 1 | 2016 | 15 | 0.510 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 331 | 0.510 |
Why?
| | Metaplasia | 10 | 2023 | 58 | 0.510 |
Why?
| | Diagnostic Tests, Routine | 1 | 2017 | 110 | 0.500 |
Why?
| | Cohort Studies | 10 | 2023 | 5799 | 0.500 |
Why?
| | Carcinoembryonic Antigen | 2 | 2018 | 38 | 0.500 |
Why?
| | Documentation | 2 | 2023 | 199 | 0.500 |
Why?
| | Conscious Sedation | 2 | 2020 | 94 | 0.490 |
Why?
| | Diarrhea | 3 | 2019 | 183 | 0.490 |
Why?
| | Hospitals | 1 | 2021 | 696 | 0.490 |
Why?
| | Specimen Handling | 1 | 2017 | 182 | 0.480 |
Why?
| | Indomethacin | 3 | 2025 | 87 | 0.480 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 26 | 0.480 |
Why?
| | Adenomatous Polyps | 1 | 2015 | 10 | 0.480 |
Why?
| | Aged, 80 and over | 22 | 2025 | 7856 | 0.480 |
Why?
| | Liver Neoplasms | 4 | 2024 | 740 | 0.470 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 10 | 0.470 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 11 | 0.470 |
Why?
| | Pathology, Clinical | 1 | 2015 | 29 | 0.460 |
Why?
| | Hypnotics and Sedatives | 2 | 2020 | 214 | 0.460 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2014 | 642 | 0.460 |
Why?
| | Predictive Value of Tests | 17 | 2019 | 2070 | 0.460 |
Why?
| | Quality Improvement | 2 | 2021 | 1244 | 0.450 |
Why?
| | Jaundice, Obstructive | 1 | 2014 | 3 | 0.450 |
Why?
| | Duodenal Diseases | 1 | 2014 | 8 | 0.450 |
Why?
| | Aftercare | 4 | 2023 | 218 | 0.450 |
Why?
| | Ultrasonography, Interventional | 2 | 2019 | 155 | 0.450 |
Why?
| | Pancreaticoduodenectomy | 1 | 2016 | 129 | 0.440 |
Why?
| | Foreign-Body Migration | 1 | 2014 | 32 | 0.440 |
Why?
| | Mucous Membrane | 9 | 2015 | 125 | 0.430 |
Why?
| | Duodenum | 1 | 2014 | 74 | 0.430 |
Why?
| | Neoplasms | 3 | 2020 | 2741 | 0.430 |
Why?
| | Colectomy | 1 | 2015 | 107 | 0.430 |
Why?
| | Curriculum | 2 | 2024 | 1033 | 0.420 |
Why?
| | Cholecystectomy | 3 | 2019 | 58 | 0.420 |
Why?
| | Advisory Committees | 5 | 2014 | 220 | 0.420 |
Why?
| | Intestinal Mucosa | 4 | 2015 | 631 | 0.420 |
Why?
| | Hemorrhage | 4 | 2020 | 760 | 0.420 |
Why?
| | Recurrence | 4 | 2024 | 1110 | 0.420 |
Why?
| | Delivery of Health Care | 1 | 2021 | 961 | 0.410 |
Why?
| | Multimodal Imaging | 1 | 2014 | 120 | 0.410 |
Why?
| | Logistic Models | 9 | 2025 | 2086 | 0.410 |
Why?
| | Risk Assessment | 10 | 2020 | 3490 | 0.410 |
Why?
| | Precision Medicine | 1 | 2017 | 434 | 0.400 |
Why?
| | Internship and Residency | 3 | 2021 | 1235 | 0.400 |
Why?
| | Polyps | 1 | 2013 | 12 | 0.400 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2012 | 9 | 0.390 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 58 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 6 | 2020 | 2746 | 0.390 |
Why?
| | Education, Medical, Continuing | 3 | 2022 | 133 | 0.390 |
Why?
| | Positron-Emission Tomography | 1 | 2014 | 310 | 0.390 |
Why?
| | Enteral Nutrition | 3 | 2021 | 202 | 0.380 |
Why?
| | Educational Measurement | 4 | 2025 | 318 | 0.380 |
Why?
| | Reproducibility of Results | 16 | 2023 | 3348 | 0.380 |
Why?
| | Gastroenterologists | 2 | 2022 | 16 | 0.380 |
Why?
| | Osteitis Deformans | 2 | 2023 | 7 | 0.380 |
Why?
| | Cholecystitis | 3 | 2024 | 23 | 0.380 |
Why?
| | Multivariate Analysis | 7 | 2021 | 1490 | 0.370 |
Why?
| | Health Care Costs | 1 | 2015 | 424 | 0.370 |
Why?
| | Pancreatitis, Chronic | 3 | 2024 | 61 | 0.370 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 94 | 0.370 |
Why?
| | Pandemics | 6 | 2023 | 1653 | 0.360 |
Why?
| | Manometry | 3 | 2021 | 97 | 0.350 |
Why?
| | Neuroendocrine Tumors | 3 | 2018 | 109 | 0.350 |
Why?
| | Laparoscopy | 1 | 2015 | 463 | 0.340 |
Why?
| | Propofol | 1 | 2011 | 89 | 0.340 |
Why?
| | Sex Factors | 5 | 2021 | 2058 | 0.340 |
Why?
| | Myotomy | 2 | 2021 | 15 | 0.340 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 374 | 0.340 |
Why?
| | Coronavirus Infections | 3 | 2020 | 371 | 0.340 |
Why?
| | Video Recording | 7 | 2019 | 190 | 0.340 |
Why?
| | Hypotension | 1 | 2011 | 122 | 0.330 |
Why?
| | Pathology, Surgical | 1 | 2010 | 9 | 0.330 |
Why?
| | Consensus | 4 | 2024 | 704 | 0.330 |
Why?
| | Evidence-Based Medicine | 6 | 2024 | 750 | 0.330 |
Why?
| | Duodenal Neoplasms | 2 | 2023 | 24 | 0.320 |
Why?
| | Education, Medical | 1 | 2013 | 270 | 0.310 |
Why?
| | Diagnostic Techniques, Digestive System | 2 | 2019 | 12 | 0.310 |
Why?
| | Irritable Bowel Syndrome | 2 | 2019 | 29 | 0.300 |
Why?
| | Wandering Spleen | 1 | 2008 | 2 | 0.300 |
Why?
| | Odds Ratio | 4 | 2018 | 1052 | 0.300 |
Why?
| | Hernia, Hiatal | 4 | 2021 | 40 | 0.300 |
Why?
| | Informed Consent | 3 | 2022 | 189 | 0.300 |
Why?
| | Histocytochemistry | 4 | 2013 | 80 | 0.290 |
Why?
| | Computer-Assisted Instruction | 4 | 2024 | 68 | 0.290 |
Why?
| | Survival Rate | 3 | 2021 | 1970 | 0.290 |
Why?
| | Image Enhancement | 6 | 2018 | 191 | 0.280 |
Why?
| | Tertiary Care Centers | 4 | 2016 | 178 | 0.280 |
Why?
| | Surgeons | 2 | 2022 | 335 | 0.270 |
Why?
| | Microscopy, Confocal | 5 | 2020 | 324 | 0.270 |
Why?
| | Decision Trees | 2 | 2019 | 82 | 0.270 |
Why?
| | Obesity | 5 | 2025 | 3004 | 0.270 |
Why?
| | Proton Pump Inhibitors | 3 | 2022 | 108 | 0.270 |
Why?
| | Liver Transplantation | 1 | 2014 | 766 | 0.270 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2025 | 348 | 0.270 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2026 | 358 | 0.260 |
Why?
| | Malignant Catarrh | 1 | 2006 | 1 | 0.260 |
Why?
| | Goats | 1 | 2006 | 27 | 0.260 |
Why?
| | Fluid Therapy | 2 | 2018 | 138 | 0.260 |
Why?
| | Sphincter of Oddi | 3 | 2024 | 5 | 0.260 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2024 | 353 | 0.260 |
Why?
| | Herpesviridae | 1 | 2006 | 22 | 0.260 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 2 | 2019 | 24 | 0.250 |
Why?
| | Mass Screening | 5 | 2022 | 1310 | 0.250 |
Why?
| | Age Factors | 5 | 2020 | 3292 | 0.250 |
Why?
| | Picolinic Acids | 1 | 2006 | 10 | 0.250 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2006 | 26 | 0.240 |
Why?
| | Carrier State | 1 | 2006 | 71 | 0.240 |
Why?
| | Prevalence | 7 | 2023 | 2772 | 0.240 |
Why?
| | Natural Orifice Endoscopic Surgery | 3 | 2021 | 35 | 0.240 |
Why?
| | Lithotripsy | 3 | 2024 | 46 | 0.240 |
Why?
| | Pancreatic Pseudocyst | 3 | 2024 | 17 | 0.230 |
Why?
| | Follow-Up Studies | 10 | 2015 | 5200 | 0.230 |
Why?
| | Decision Support Techniques | 3 | 2019 | 431 | 0.230 |
Why?
| | Thinness | 1 | 2025 | 96 | 0.230 |
Why?
| | Singapore | 1 | 2025 | 23 | 0.230 |
Why?
| | Sphincter of Oddi Dysfunction | 1 | 2024 | 1 | 0.230 |
Why?
| | Osteoclasts | 3 | 2023 | 51 | 0.230 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1498 | 0.230 |
Why?
| | Cattle Diseases | 1 | 2005 | 25 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2363 | 0.220 |
Why?
| | Feasibility Studies | 6 | 2024 | 1018 | 0.220 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2017 | 277 | 0.220 |
Why?
| | Heartburn | 2 | 2021 | 12 | 0.220 |
Why?
| | Constriction, Pathologic | 5 | 2020 | 238 | 0.220 |
Why?
| | DNA, Viral | 1 | 2006 | 366 | 0.220 |
Why?
| | Metabolic Diseases | 1 | 2025 | 114 | 0.220 |
Why?
| | Escherichia coli Infections | 1 | 2005 | 117 | 0.210 |
Why?
| | Hypoxia | 1 | 2011 | 1164 | 0.210 |
Why?
| | Program Evaluation | 2 | 2020 | 928 | 0.210 |
Why?
| | Drug Monitoring | 1 | 2026 | 217 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 2 | 2026 | 878 | 0.210 |
Why?
| | Sheep | 1 | 2006 | 874 | 0.210 |
Why?
| | Bile Duct Diseases | 2 | 2014 | 12 | 0.210 |
Why?
| | Biomarkers | 6 | 2025 | 4174 | 0.210 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2023 | 23 | 0.210 |
Why?
| | G-Protein-Coupled Receptor Kinase 3 | 1 | 2023 | 2 | 0.200 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 89 | 0.200 |
Why?
| | Ergonomics | 1 | 2023 | 24 | 0.200 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2023 | 14 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 3 | 2020 | 908 | 0.200 |
Why?
| | Cytodiagnosis | 2 | 2020 | 32 | 0.200 |
Why?
| | Cholelithiasis | 1 | 2023 | 37 | 0.200 |
Why?
| | Case-Control Studies | 6 | 2025 | 3588 | 0.190 |
Why?
| | Cause of Death | 1 | 2025 | 440 | 0.190 |
Why?
| | Microsurgery | 1 | 2023 | 77 | 0.190 |
Why?
| | Carcinoid Tumor | 1 | 2022 | 23 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 98 | 0.190 |
Why?
| | Appendiceal Neoplasms | 1 | 2022 | 29 | 0.190 |
Why?
| | Bone Resorption | 1 | 2023 | 84 | 0.190 |
Why?
| | Hospitalization | 4 | 2026 | 2255 | 0.190 |
Why?
| | Forecasting | 1 | 2024 | 384 | 0.190 |
Why?
| | Fluorouracil | 1 | 2023 | 206 | 0.190 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 64 | 0.190 |
Why?
| | Gastrointestinal Tract | 1 | 2025 | 204 | 0.190 |
Why?
| | Medicare | 2 | 2021 | 799 | 0.190 |
Why?
| | Surgical Instruments | 3 | 2022 | 50 | 0.190 |
Why?
| | Biomedical Research | 2 | 2020 | 703 | 0.190 |
Why?
| | Metabolome | 1 | 2025 | 366 | 0.180 |
Why?
| | Health Care Surveys | 3 | 2020 | 565 | 0.180 |
Why?
| | Diverticulum, Esophageal | 1 | 2021 | 4 | 0.180 |
Why?
| | Gastrectomy | 2 | 2023 | 133 | 0.180 |
Why?
| | Weight Loss | 2 | 2021 | 789 | 0.180 |
Why?
| | Aspirin | 1 | 2025 | 385 | 0.180 |
Why?
| | Esophageal Sphincter, Upper | 1 | 2021 | 7 | 0.180 |
Why?
| | Proton Pumps | 1 | 2021 | 8 | 0.180 |
Why?
| | Professional Practice Location | 2 | 2019 | 29 | 0.180 |
Why?
| | Biopsy, Needle | 2 | 2020 | 187 | 0.180 |
Why?
| | Dietary Supplements | 1 | 2006 | 566 | 0.180 |
Why?
| | Disease Outbreaks | 1 | 2005 | 419 | 0.180 |
Why?
| | Single-Blind Method | 5 | 2014 | 288 | 0.170 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2021 | 13 | 0.170 |
Why?
| | Trefoil Factor-3 | 1 | 2020 | 5 | 0.170 |
Why?
| | Internationality | 2 | 2020 | 158 | 0.170 |
Why?
| | Gastric Outlet Obstruction | 1 | 2020 | 12 | 0.170 |
Why?
| | Formative Feedback | 2 | 2024 | 29 | 0.170 |
Why?
| | Oral Submucous Fibrosis | 1 | 2020 | 2 | 0.170 |
Why?
| | Radiography, Abdominal | 2 | 2012 | 44 | 0.170 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 109 | 0.170 |
Why?
| | Stomach | 2 | 2012 | 110 | 0.170 |
Why?
| | Midazolam | 1 | 2020 | 72 | 0.170 |
Why?
| | Varicose Veins | 1 | 2020 | 16 | 0.170 |
Why?
| | Equipment Contamination | 1 | 2021 | 71 | 0.170 |
Why?
| | Betacoronavirus | 2 | 2020 | 276 | 0.170 |
Why?
| | Escherichia coli | 1 | 2005 | 838 | 0.160 |
Why?
| | Laparotomy | 2 | 2012 | 115 | 0.160 |
Why?
| | Esophageal and Gastric Varices | 1 | 2020 | 35 | 0.160 |
Why?
| | United Arab Emirates | 1 | 2020 | 7 | 0.160 |
Why?
| | Cost-Benefit Analysis | 3 | 2015 | 618 | 0.160 |
Why?
| | Emergencies | 1 | 2021 | 179 | 0.160 |
Why?
| | Morbidity | 1 | 2021 | 322 | 0.160 |
Why?
| | Cecum | 1 | 2019 | 32 | 0.160 |
Why?
| | Neostigmine | 1 | 2019 | 16 | 0.160 |
Why?
| | Body Fluids | 1 | 2020 | 70 | 0.160 |
Why?
| | Colostomy | 1 | 2019 | 28 | 0.160 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2020 | 38 | 0.160 |
Why?
| | Disease Transmission, Infectious | 1 | 2020 | 69 | 0.160 |
Why?
| | Survival Analysis | 2 | 2015 | 1319 | 0.160 |
Why?
| | Accreditation | 1 | 2020 | 92 | 0.160 |
Why?
| | Dissection | 2 | 2020 | 55 | 0.160 |
Why?
| | Perception | 1 | 2022 | 376 | 0.150 |
Why?
| | Mirizzi Syndrome | 1 | 2019 | 2 | 0.150 |
Why?
| | Injections, Intramuscular | 1 | 2019 | 131 | 0.150 |
Why?
| | Disinfection | 1 | 2021 | 128 | 0.150 |
Why?
| | Saliva | 1 | 2021 | 245 | 0.150 |
Why?
| | Urinary Calculi | 1 | 2019 | 10 | 0.150 |
Why?
| | India | 3 | 2018 | 208 | 0.150 |
Why?
| | Ascites | 1 | 2019 | 47 | 0.150 |
Why?
| | ROC Curve | 4 | 2015 | 586 | 0.150 |
Why?
| | Propensity Score | 2 | 2025 | 328 | 0.150 |
Why?
| | Research Design | 2 | 2020 | 1143 | 0.150 |
Why?
| | Anastomotic Leak | 1 | 2019 | 43 | 0.150 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2020 | 310 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2023 | 273 | 0.150 |
Why?
| | Mastitis, Bovine | 1 | 2018 | 2 | 0.150 |
Why?
| | Feedback | 1 | 2019 | 179 | 0.150 |
Why?
| | Chronic Disease | 3 | 2019 | 1816 | 0.150 |
Why?
| | Infection Control | 1 | 2020 | 167 | 0.150 |
Why?
| | Esophageal Mucosa | 1 | 2018 | 22 | 0.150 |
Why?
| | Phage Therapy | 1 | 2018 | 17 | 0.150 |
Why?
| | Fluoroscopy | 1 | 2019 | 169 | 0.140 |
Why?
| | Plastics | 2 | 2018 | 50 | 0.140 |
Why?
| | Esophagogastric Junction | 3 | 2021 | 52 | 0.140 |
Why?
| | Gallstones | 1 | 2018 | 33 | 0.140 |
Why?
| | Clinical Protocols | 1 | 2019 | 273 | 0.140 |
Why?
| | Colonoscopes | 3 | 2014 | 5 | 0.140 |
Why?
| | Quality-Adjusted Life Years | 2 | 2015 | 113 | 0.140 |
Why?
| | Health Status Disparities | 1 | 2021 | 297 | 0.140 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.140 |
Why?
| | Mortality | 1 | 2020 | 358 | 0.140 |
Why?
| | Markov Chains | 2 | 2015 | 126 | 0.140 |
Why?
| | Aneurysm, False | 1 | 2018 | 45 | 0.140 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2017 | 21 | 0.140 |
Why?
| | Reference Standards | 1 | 2018 | 186 | 0.140 |
Why?
| | Cardia | 2 | 2007 | 2 | 0.130 |
Why?
| | Prognosis | 3 | 2017 | 4073 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1865 | 0.130 |
Why?
| | Medical Staff Privileges | 1 | 2017 | 5 | 0.130 |
Why?
| | Education | 1 | 2017 | 109 | 0.130 |
Why?
| | Optical Imaging | 2 | 2018 | 66 | 0.130 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2892 | 0.130 |
Why?
| | MicroRNAs | 2 | 2015 | 689 | 0.130 |
Why?
| | Credentialing | 1 | 2017 | 21 | 0.130 |
Why?
| | Cattle | 3 | 2018 | 998 | 0.130 |
Why?
| | Palliative Care | 2 | 2021 | 817 | 0.130 |
Why?
| | Bacteriophages | 1 | 2018 | 107 | 0.130 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 71 | 0.130 |
Why?
| | Upper Gastrointestinal Tract | 1 | 2016 | 5 | 0.130 |
Why?
| | Leiomyoma | 1 | 2017 | 56 | 0.130 |
Why?
| | Quality of Life | 2 | 2024 | 2999 | 0.130 |
Why?
| | Research | 1 | 2020 | 455 | 0.130 |
Why?
| | Immunoassay | 1 | 2017 | 113 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2020 | 334 | 0.120 |
Why?
| | Patient Discharge | 1 | 2023 | 932 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 660 | 0.120 |
Why?
| | Chemoprevention | 2 | 2014 | 95 | 0.120 |
Why?
| | Bariatric Surgery | 1 | 2019 | 218 | 0.120 |
Why?
| | Analysis of Variance | 1 | 2018 | 1320 | 0.120 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2016 | 76 | 0.120 |
Why?
| | Global Health | 1 | 2018 | 386 | 0.120 |
Why?
| | Antibiotic Prophylaxis | 1 | 2016 | 122 | 0.110 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 59 | 0.110 |
Why?
| | Physicians | 1 | 2024 | 934 | 0.110 |
Why?
| | Metals | 3 | 2023 | 140 | 0.110 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5929 | 0.110 |
Why?
| | Teaching | 1 | 2017 | 237 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 222 | 0.110 |
Why?
| | Intestinal Fistula | 1 | 2014 | 17 | 0.110 |
Why?
| | Cryosurgery | 1 | 2015 | 47 | 0.110 |
Why?
| | Administration, Rectal | 2 | 2024 | 13 | 0.110 |
Why?
| | Body Mass Index | 4 | 2025 | 2382 | 0.110 |
Why?
| | Colorectal Surgery | 1 | 2014 | 30 | 0.110 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 196 | 0.110 |
Why?
| | Staphylococcal Infections | 1 | 2018 | 392 | 0.100 |
Why?
| | Goblet Cells | 1 | 2013 | 22 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1243 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 125 | 0.100 |
Why?
| | Suture Techniques | 1 | 2014 | 128 | 0.100 |
Why?
| | Health Status | 1 | 2019 | 823 | 0.100 |
Why?
| | Bone Density | 1 | 2017 | 494 | 0.100 |
Why?
| | Patient Participation | 1 | 2017 | 432 | 0.100 |
Why?
| | Animals, Newborn | 2 | 2006 | 863 | 0.100 |
Why?
| | Primary Health Care | 2 | 2022 | 1799 | 0.100 |
Why?
| | Light | 2 | 2013 | 394 | 0.100 |
Why?
| | Multidetector Computed Tomography | 1 | 2013 | 40 | 0.100 |
Why?
| | Jejunum | 1 | 2012 | 32 | 0.100 |
Why?
| | Polymerase Chain Reaction | 2 | 2006 | 1056 | 0.100 |
Why?
| | Equipment Design | 3 | 2021 | 525 | 0.100 |
Why?
| | Mediastinum | 1 | 2012 | 22 | 0.100 |
Why?
| | Feces | 2 | 2026 | 504 | 0.090 |
Why?
| | Young Adult | 8 | 2025 | 13673 | 0.090 |
Why?
| | Peptides | 1 | 2017 | 978 | 0.090 |
Why?
| | Decision Making | 3 | 2023 | 961 | 0.090 |
Why?
| | Anesthetics, Intravenous | 1 | 2011 | 64 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2011 | 202 | 0.090 |
Why?
| | Abdomen | 1 | 2012 | 136 | 0.090 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1261 | 0.090 |
Why?
| | Patient Selection | 1 | 2015 | 688 | 0.090 |
Why?
| | Guidelines as Topic | 1 | 2012 | 273 | 0.080 |
Why?
| | Adrenal Glands | 1 | 2011 | 80 | 0.080 |
Why?
| | Intestines | 1 | 2013 | 357 | 0.080 |
Why?
| | Proteomics | 1 | 2017 | 1134 | 0.080 |
Why?
| | Esophagitis | 2 | 2007 | 68 | 0.080 |
Why?
| | Esophageal pH Monitoring | 1 | 2009 | 23 | 0.080 |
Why?
| | Veterans | 1 | 2021 | 1514 | 0.080 |
Why?
| | Adolescent | 8 | 2025 | 22007 | 0.080 |
Why?
| | North America | 2 | 2020 | 306 | 0.080 |
Why?
| | Software | 1 | 2014 | 676 | 0.080 |
Why?
| | Gastric Acid | 1 | 2009 | 14 | 0.080 |
Why?
| | Antacids | 1 | 2009 | 16 | 0.080 |
Why?
| | Remission Induction | 1 | 2009 | 309 | 0.070 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2017 | 10 | 0.070 |
Why?
| | Hematoporphyrin Photoradiation | 1 | 2007 | 1 | 0.070 |
Why?
| | Patient Care Planning | 1 | 2009 | 155 | 0.070 |
Why?
| | Colonography, Computed Tomographic | 1 | 2007 | 8 | 0.070 |
Why?
| | Gastric Fundus | 1 | 2007 | 3 | 0.070 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 18 | 0.070 |
Why?
| | Algorithms | 3 | 2026 | 1763 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1052 | 0.060 |
Why?
| | Plasmapheresis | 1 | 2006 | 24 | 0.060 |
Why?
| | Gastritis | 1 | 2007 | 110 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2026 | 38 | 0.060 |
Why?
| | Overweight | 2 | 2025 | 587 | 0.060 |
Why?
| | CDX2 Transcription Factor | 1 | 2025 | 1 | 0.060 |
Why?
| | Dairying | 1 | 2005 | 8 | 0.060 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 278 | 0.060 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 10 | 0.060 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.060 |
Why?
| | Hyperlipidemias | 1 | 2025 | 125 | 0.060 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2025 | 74 | 0.050 |
Why?
| | Image-Guided Biopsy | 2 | 2015 | 39 | 0.050 |
Why?
| | Virulence | 1 | 2005 | 268 | 0.050 |
Why?
| | DNA Primers | 1 | 2005 | 510 | 0.050 |
Why?
| | Seasons | 1 | 2006 | 546 | 0.050 |
Why?
| | Glypicans | 1 | 2023 | 11 | 0.050 |
Why?
| | DNA, Bacterial | 1 | 2005 | 339 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 854 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2026 | 418 | 0.050 |
Why?
| | Animals | 5 | 2023 | 37657 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 165 | 0.050 |
Why?
| | United Kingdom | 1 | 2023 | 322 | 0.050 |
Why?
| | Tumor Burden | 2 | 2015 | 312 | 0.050 |
Why?
| | Biological Products | 1 | 2026 | 237 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1819 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2006 | 482 | 0.050 |
Why?
| | Pain Measurement | 1 | 2024 | 554 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 249 | 0.050 |
Why?
| | Appendectomy | 1 | 2022 | 89 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2025 | 349 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 221 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 457 | 0.040 |
Why?
| | Technology | 1 | 2022 | 94 | 0.040 |
Why?
| | Colonic Diseases | 2 | 2014 | 36 | 0.040 |
Why?
| | Osteogenesis | 1 | 2023 | 199 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2024 | 392 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2024 | 339 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 80 | 0.040 |
Why?
| | Lifting | 1 | 2020 | 4 | 0.040 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 185 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5636 | 0.040 |
Why?
| | Cough | 1 | 2021 | 129 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 573 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1983 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 434 | 0.040 |
Why?
| | Granuloma | 1 | 2020 | 97 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 55 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 129 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 232 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 2012 | 578 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1254 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 583 | 0.040 |
Why?
| | Myoviridae | 1 | 2018 | 1 | 0.040 |
Why?
| | Podoviridae | 1 | 2018 | 1 | 0.040 |
Why?
| | Pilot Projects | 3 | 2011 | 1820 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 532 | 0.040 |
Why?
| | Rural Population | 1 | 2023 | 604 | 0.040 |
Why?
| | Coloring Agents | 1 | 2018 | 96 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2018 | 157 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 419 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2020 | 282 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2018 | 336 | 0.030 |
Why?
| | Cyst Fluid | 1 | 2018 | 21 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 830 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1556 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2019 | 145 | 0.030 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2018 | 52 | 0.030 |
Why?
| | Hospitals, University | 1 | 2018 | 175 | 0.030 |
Why?
| | User-Computer Interface | 1 | 2018 | 164 | 0.030 |
Why?
| | Whole Genome Sequencing | 1 | 2018 | 167 | 0.030 |
Why?
| | Communication | 1 | 2024 | 945 | 0.030 |
Why?
| | Granular Cell Tumor | 1 | 2017 | 9 | 0.030 |
Why?
| | Review Literature as Topic | 1 | 2017 | 72 | 0.030 |
Why?
| | Lipoma | 1 | 2017 | 16 | 0.030 |
Why?
| | Choristoma | 1 | 2017 | 20 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2902 | 0.030 |
Why?
| | Cancer Pain | 1 | 2017 | 35 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 460 | 0.030 |
Why?
| | Choledochal Cyst | 1 | 2016 | 17 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2025 | 2828 | 0.030 |
Why?
| | Gastroscopes | 1 | 2016 | 3 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 433 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2025 | 1074 | 0.030 |
Why?
| | Genome, Viral | 1 | 2018 | 223 | 0.030 |
Why?
| | Duodenoscopes | 1 | 2016 | 7 | 0.030 |
Why?
| | Biliary Tract Neoplasms | 1 | 2016 | 31 | 0.030 |
Why?
| | Embolism, Air | 1 | 2016 | 14 | 0.030 |
Why?
| | Exons | 1 | 2017 | 353 | 0.030 |
Why?
| | Nerve Block | 1 | 2017 | 97 | 0.030 |
Why?
| | Cholangitis, Sclerosing | 1 | 2016 | 56 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 645 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1116 | 0.030 |
Why?
| | Viral Proteins | 1 | 2018 | 369 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2504 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 3469 | 0.030 |
Why?
| | Child, Preschool | 2 | 2022 | 11457 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 737 | 0.030 |
Why?
| | Bone and Bones | 1 | 2017 | 317 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2017 | 464 | 0.030 |
Why?
| | Child | 3 | 2021 | 22308 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2574 | 0.030 |
Why?
| | Equipment Failure | 1 | 2014 | 111 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2021 | 666 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 1122 | 0.030 |
Why?
| | Proteome | 1 | 2018 | 483 | 0.030 |
Why?
| | Pain | 1 | 2019 | 781 | 0.030 |
Why?
| | Pathology | 1 | 2013 | 23 | 0.030 |
Why?
| | Health Status Indicators | 1 | 2014 | 163 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 2003 | 0.030 |
Why?
| | Community Health Centers | 1 | 2013 | 63 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 464 | 0.020 |
Why?
| | Mice | 2 | 2023 | 18048 | 0.020 |
Why?
| | Color | 1 | 2013 | 82 | 0.020 |
Why?
| | Community Health Services | 1 | 2014 | 233 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3166 | 0.020 |
Why?
| | Adenoma, Villous | 1 | 2012 | 2 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 316 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1444 | 0.020 |
Why?
| | Gastroscopy | 1 | 2011 | 18 | 0.020 |
Why?
| | Sentinel Surveillance | 1 | 2011 | 48 | 0.020 |
Why?
| | Digestive System Neoplasms | 1 | 2011 | 9 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 116 | 0.020 |
Why?
| | Risk | 1 | 2013 | 904 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3068 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 482 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 528 | 0.020 |
Why?
| | Genetic Markers | 1 | 2011 | 343 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4013 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4208 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 987 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 857 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2009 | 556 | 0.020 |
Why?
| | Motor Activity | 1 | 2013 | 717 | 0.020 |
Why?
| | Geography | 1 | 2008 | 201 | 0.020 |
Why?
| | Diagnostic Equipment | 1 | 2007 | 4 | 0.020 |
Why?
| | Helicobacter Infections | 1 | 2007 | 30 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4610 | 0.020 |
Why?
| | Helicobacter pylori | 1 | 2007 | 42 | 0.020 |
Why?
| | Fraud | 1 | 2007 | 10 | 0.020 |
Why?
| | Selenium | 1 | 2007 | 49 | 0.020 |
Why?
| | Electrocoagulation | 1 | 2007 | 35 | 0.020 |
Why?
| | Gastric Mucosa | 1 | 2007 | 53 | 0.020 |
Why?
| | Quality Control | 1 | 2007 | 171 | 0.020 |
Why?
| | Laser Coagulation | 1 | 2007 | 71 | 0.020 |
Why?
| | Risk Management | 1 | 2007 | 93 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1737 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5887 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2007 | 328 | 0.020 |
Why?
| | Capillaries | 1 | 2007 | 125 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 772 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 326 | 0.010 |
Why?
| | Monocytes | 1 | 2007 | 579 | 0.010 |
Why?
| | Health Policy | 1 | 2007 | 403 | 0.010 |
Why?
| | Infant | 1 | 2018 | 9818 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2166 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1306 | 0.010 |
Why?
| | Comorbidity | 1 | 2007 | 1662 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2599 | 0.010 |
Why?
| | Neutrophils | 1 | 2007 | 1282 | 0.010 |
Why?
| | Smoking | 1 | 2007 | 1601 | 0.010 |
Why?
| | Diet | 1 | 2007 | 1282 | 0.010 |
Why?
|
|
Wani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|